Endocrinology Search
Endocrinology Endocrinology
hypomagnesemia%20-and-%20hypermagnesemia
HYPOMAGNESEMIA & HYPERMAGNESEMIA
Hypomagnesemia is having a serum magnesium concentration of <1.3 mEq/L.
Patients with mild hypomagnesemia is asymptomatic and have usually a serum Mg >0.5 mmol/L. While those with moderate-severe hypomagnesemia, the patient is symptomatic and have serum Mg <5 mmol/L.
Hypermagnesemia signs and symptoms usually do not appear unless Mg >2 mmol/L (5 mg/dL). It rarely occurs and usually iatrogenic.
  1. Agus ZS. Hypomagnesemia. J Am Soc Nephrol. 1999 Jul;10(7):1616-1622. PMID: 10405219
  2. Dacey MJ. Hypomagnesemic disorders. Crit Care Clin. 2001 Jan;17(1):155-173. PMID: 11219227
  3. Weisinger JR, Bellorin-Font E. Electrolyte quintet: magnesium and phosphorus. Lancet. 1998 Aug;352(9125):391-396. PMID: 9717944
  4. Diseases of the parathyroid gland and other hyper- and hypocalcemic disorders. Harrison's Online: McGraw-Hill Companies; 2003.
  5. Introduction to bone and mineral metabolism. Harrison's Online: McGraw-Hill Companies; 2003.
  6. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  7. Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010 Nov;122(Suppl 18):S829-S861. doi: 10.1161/CIRCULATIONAHA.110.971069. PMID: 20956228
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Newly approved oral anti-diabetic medication now available in Malaysia
Hannah Wong, 30 Sep 2019

Taisho Pharmaceutical launches Lusefi®, an oral anti-diabetic medication for type 2 diabetes mellitus (T2DM). The medication is expected to lower blood glucose and provide adequate glycaemic control, serving as a new alternative prescription for T2DM. Lusefi, with its active ingredient luseogliflozin hydrate, is available in the form of 2.5 mg and 5 mg tablets.
DIABESITY AND THE ROLE OF DIABETIC-SPECIFIC FORMULA IN IMPROVING DIABETES AND OBESITY OUTCOMES
02 May 2019
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
Dapagliflozin slows eGFR decline in diabetics
Tristan Manalac, 19 Nov 2019
Dapagliflozin is able to delay renal disease progression among patients with type 2 diabetes, even in those with normal kidney function, according to a study presented at the recently concluded Kidney Week 2019 of the American Society of Nephrology (ASN 2019).
Diabetes mellitus negatively influences pancreatic cancer outcomes
07 Oct 2019
In pancreatic cancer patients undergoing chemotherapy, the presence of diabetes mellitus is associated with reduced survival and larger tumour, as well as with increased risk of death after treatment, according to a meta-analysis.